טוען...

Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials

BACKGROUND: Response rate (RR), the most common early means of assessing oncology drugs, is not suitable as the sole endpoint for phase II trials of drugs which induce disease stability but not regression. Time to progression (TTP) may be more sensitive to such agents, but induces recruitment delays...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Goffin, John R, Pond, Greg R
פורמט: Artigo
שפה:Inglês
יצא לאור: BioMed Central 2011
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3259049/
https://ncbi.nlm.nih.gov/pubmed/22151297
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2288-11-164
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!